CTC or CEA: Choosing Reliable Markers for Metastatic Colorectal Cancer
),
(1) Fellows of the Indonesian Society of Internal Medicine; Division of Gastroentero-hepatology, Department of Internal Medicine, Faculty of Medicine-Dr. Soetomo Teaching Hospital, Universitas Airlangga, Surabaya
Corresponding Author
Abstract
References
Argilés G, Tabernero J, Labianca R, Hochhauser D, Salazar R, Iveson T, et al. Localised colon cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(10):1291–305.
World Health Organization. Colorectal cancer. 2023.
National Cancer Institute. Why is colorectal cancer rising rapidly among young adults? [Internet]. 2020. Available from: https://www.cancer.gov/news-events/cancer-currents-blog/2020/colorectal-cancer-rising-younger-adults
Hamilton W, Bailey SER. Colorectal cancer in symptomatic patients: how to improve the diagnostic pathway. Best Pract Res Clin Gastroenterol. 2023;66:101842.
Roshandel G, Ghasemi-Kebria F, Malekzadeh R. Colorectal cancer: epidemiology, risk factors, and prevention. Cancers (Basel). 2024;16(8):1530.
National Health Commission of the People’s Republic of China. National guidelines for diagnosis and treatment of colorectal cancer 2020 in China. Chin J Cancer Res. 2020;32(4):415–45.
Cervantes A, Adam R, Roselló S, Arnold D, Normanno N, Taïeb J, et al. Metastatic colorectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(1):10–32.
Saadi S, Aarab M, Tabyaoui I, Jouti NT. Circulating tumor cells in colorectal cancer: a review of detection methods and clinical relevance. Contemp Oncol (Pozn). 2023;27(3):123–31.
Chu HY, Yang CY, Yeh PH, Hsu CJ, Chang LW, Chan WJ, et al. Highly correlated recurrence prognosis in patients with metastatic colorectal cancer by synergistic consideration of circulating tumor cells/microemboli and tumor markers CEA/CA19-9. Cells. 2021;10(5):1149.
Ashworth T. A case of cancer in which cells similar to those in the tumours were seen in the blood after death. Aust Med J. 1869;14:146–7.
Baek DH, Kim GH, Song GA, Han IS, Park EY, Kim HS, et al. Clinical potential of circulating tumor cells in colorectal cancer: a prospective study. Clin Transl Gastroenterol. 2019;10(7):e00055.
Capuozzo M, Ferrara F, Santorsola M, Zovi A, Ottaiano A. Circulating tumor cells as predictive and prognostic biomarkers in solid tumors. Cells. 2023;12(22):3799.
Tsai WS, Chen JS, Shao HJ, Wu JC, Lai JM, Lu SH, et al. Circulating tumor cell count correlates with colorectal neoplasm progression and is a prognostic marker for distant metastasis in non-metastatic patients. Sci Rep. 2016;6:24517.
Primrose JN, Perera R, Gray A, Rose P, Fuller A, Corkhill A, et al. Effect of 3 to 5 years of scheduled CEA and CT follow-up to detect recurrence of colorectal cancer. JAMA. 2014;311(3):263–70.
Kankanala V, Zubair M, Mukkamalla S. Carcinoembryonic antigen. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024.
Niedzielska J, Jastrzębski T. Carcinoembryonic antigen (CEA): origin, role in oncology, and concentrations in serum and peritoneal fluid. J Clin Med. 2025;14(9):3189.
Titu S, Ilies RA, Mocan T, Irimie A, Gata VA, Lisencu CI. Evaluation of carcinoembryonic antigen as a prognostic marker for colorectal cancer relapse: insights from postoperative surveillance. Med Sci (Basel). 2025;13(4):229.
Moretto R, Rossini D, Conca V, Lonardi S, Rasola C, Antoniotti C, et al. CEA increase as a marker of disease progression after first-line induction therapy in metastatic colorectal cancer patients: a pooled analysis of the TRIBE and TRIBE2 studies. Br J Cancer. 2021;125(6):839–45.
Hall C, Clarke L, Pal A, Buchwald P, Eglinton T, Wakeman C, et al. A review of the role of carcinoembryonic antigen in clinical practice. Ann Coloproctol. 2019;35(6):294–305.
Malla M, Loree JM, Kasi PM, Parikh AR. Using circulating tumor DNA in colorectal cancer: current and evolving practices. J Clin Oncol. 2022;40(24):2846–57.
Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014;6(224):224ra24.
Vacante M, Borzì AM, Basile F, Biondi A. Biomarkers in colorectal cancer: current clinical utility and future perspectives. World J Clin Cases. 2018;6(15):869–81.
Takeda M, Yoshida S, Inoue T, Sekido Y, Hata T, Hamabe A, et al. The role of KRAS mutations in colorectal cancer: biological insights, clinical implications, and future therapeutic perspectives. Cancers (Basel). 2025;17(3):428.
Article Metrics
Abstract View
: 128 times
Download : 102 times
DOI: 10.24871/2632025201-203
Refbacks
- There are currently no refbacks.
